Approaches to gene therapy with sodium/iodide symporter

C. Spitzweg, J. C. Morris

Research output: Contribution to journalShort surveypeer-review

20 Scopus citations


Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.

Original languageEnglish (US)
Pages (from-to)56-59
Number of pages4
JournalExperimental and Clinical Endocrinology and Diabetes
Issue number1
StatePublished - 2001


  • Gene therapy
  • Prostate cancer
  • Sodium/iodide symporter (NIS)

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Approaches to gene therapy with sodium/iodide symporter'. Together they form a unique fingerprint.

Cite this